The company announces that its subsidiary's licensed drug CRB-701 (SYS6002) has received US FDA approval to initiate a Phase III clinical trial for second-line oropharyngeal squamous cell carcinoma. The trial aims to evaluate efficacy and safety, seeking accelerated approval based on ORR and full approval based on OS. Patient enrollment is expected to begin in Q3 2026.
Summary generated by AI · Always verify with source document
Stock Code: 300765
Stock Abbreviation: CStone Pharma
Announcement No.: 2026-068
CStone Pharmaceuticals Co., Ltd.
Announcement on the Approval of the Investigational Clinical Trial Protocol for CRB-701 (SYS6002) Licensed by a Subsidiary to a Third Party by the US FDA
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.